ஷில்பா உயிரியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Shilpa Medicare rallied 10.46% to Rs 503 after the company said it has entered into a three-year definitive agreement with Dr. Reddy s Laboratories for production and supply of the Sputnik V vaccine.In an exchange filing on Monday, Shilpa Medicare said that through its wholly owned subsidiary, Shilpa Biologicals, will produce and supply the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production. Dr. Reddy s has partnered with HV/RDIF for clinical development of the vaccine and has distribution rights in geographies including India. Dr. Reddy s will facilitate the transfer of the sputnik technology to Shilpa Biologicals. Under the agreement, Shilpa Biologicals will be responsible for manufacture of the vaccine, while DRL is responsible fo

Shilpa medicareShilpa biologicalsSputnik lightFlexible biologicsCapital marketCovid 19 pandemic in russiaScience and technology in russiaSputnikv covid 19 vaccineDr reddys laboratoriesHarmaceuticals necV rdifShilpa medicareSputnik technologyGum manufacturingஷில்பா மருத்துவஷில்பா உயிரியல்